Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat

Cellular Immunology

Volumn 212, Issue 2, 2001, Pages 138-149

  Piechocki, Marie P ^a,b   Pilon, Shari A ^a,b   Kelly, Carmen ^a   Wei, Wei Zen ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antigen processing and presentation; CTL; ErbB 2; GA repeat; Her 2; Neu; Proteasome

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; CANCER VACCINE; CHAPERONE; DINUCLEOTIDE; GELDANAMYCIN; GLYCYLALANINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROLYLALANINE; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CHIMERA; CONTROLLED STUDY; CYTOLYSIS; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; MOUSE; NONHUMAN; NUCLEOTIDE REPEAT; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TUMOR IMMUNOLOGY;

EID: 0035885873     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1006/cimm.2001.1853     Document Type: Article

References (32)

1. The neu oncogene encodes an epidermal growth factor receptor-related protein
2. Bivalence of EGF-like ligands drives the ErbB signaling network
3. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway
4. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
5. Multiple molecular chaperones complex with misfolded large oligomeric glycoproteins in the endoplasmic reticulum
6. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases
7. c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin
8. The N-end rule: Functions, mysteries, uses
9. Existent T cell and antibody immunity to Her-2/neu protein in patients with breast cancer
10. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same Her-2/neu-derived peptide
11. Identification of naturally processed human ovarian peptides recognized by tumor-associated cytotoxic T lymphocytes
12. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
13. Heregulin beta 1 induces the down regulation and the ubiquitin-proteasome degradation pathway of p185HER2 oncoprotein
14. Setting the standards: Quality control in the secretory pathway
15. Posttranslational quality control: Folding, refolding, and degrading proteins
16. Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum
17. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA
18. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody
19. Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen
20. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
21. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1
22. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated IκBα with the proteasome: A new mechanism for selective inhibition of proteolysis
23. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells
24. FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor associated macrophages from metastatic and non-metastatic mouse mammary tumors
25. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or Her2/neu gene product
26. + T cell response: Lessons from the EBV nuclear antigen EBNA1
27. Human CD8+ T cell responses to EBV EBNA1: HLA Class I presentation of the (Gly-Ala)-containing protein requires exogenous processing
28. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
29. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
30. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
31. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake
32. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth